Aripiprazole

Generic Name: Aripiprazole

Brand Names: Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇Cl_₂N_₃O_₂

CAS Number: 129722-12-9

Unique Ingredient Identifier: 82VFR53I78

Background: Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.

Indication: Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.

Associated Conditions: Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode

Associated Therapies: Monotherapy

Clinical Trials

Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Apipe (Aripiprazole10 mg)
Drug: Abilify (Aripiprazole10 mg)

First Posted Date: 2023-04-07

Last Posted Date: 2023-04-07

Lead Sponsor: Genuine Research Center, Egypt

Target Recruit Count: 29

Registration Number: NCT05804721

Locations: 🇪🇬
Genuine Research Center GRC, Cairo, Egypt

Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT

Phase 4

Not yet recruiting

Conditions: Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia

Interventions: Drug: Aripiprazole 10 MG

First Posted Date: 2023-03-13

Last Posted Date: 2023-07-20

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 60

Registration Number: NCT05766540

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

Phase 4

Withdrawn

Conditions: Depressive Disorder, Major

Interventions: Drug: Esketamine
Drug: Aripiprazole

First Posted Date: 2022-09-26

Last Posted Date: 2024-01-05

Lead Sponsor: VA Office of Research and Development

Registration Number: NCT05554627

Locations: 🇺🇸
Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States
🇺🇸
New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States
🇺🇸
Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States

and more 23 locations

Aripiprazole in Body Focused Repetitive Behaviors

Phase 2

Not yet recruiting

Conditions: Dermatillomania
Trichotillomania (Hair-Pulling Disorder)

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2022-09-19

Last Posted Date: 2025-01-08

Lead Sponsor: University of Chicago

Target Recruit Count: 100

Registration Number: NCT05545891

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

Phase 4

Completed

Conditions: Depression
Dementia
Mild Cognitive Impairment
Treatment Resistant Depression
Treatment-Refractory Depression
Major Depressive Disorder
Late Life Depression
Geriatric Depression

Interventions: Drug: Aripiprazole Augmentation
Drug: Bupropion Augmentation
Drug: Switch to bupropion
Drug: Lithium Augmentation
Drug: Switch to nortriptyline

First Posted Date: 2022-09-08

Last Posted Date: 2024-11-25

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 87

Registration Number: NCT05531591

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
🇺🇸
Columbia University Adult and Late Life Depression Clinic, New York, New York, United States
🇺🇸
UCLA Late-Life Mood, Stress, and Wellness Research Program, Los Angeles, California, United States

and more 1 locations